全文获取类型
收费全文 | 6379篇 |
免费 | 334篇 |
国内免费 | 62篇 |
专业分类
耳鼻咽喉 | 45篇 |
儿科学 | 189篇 |
妇产科学 | 143篇 |
基础医学 | 643篇 |
口腔科学 | 146篇 |
临床医学 | 440篇 |
内科学 | 1690篇 |
皮肤病学 | 126篇 |
神经病学 | 384篇 |
特种医学 | 382篇 |
外科学 | 1142篇 |
综合类 | 18篇 |
预防医学 | 214篇 |
眼科学 | 53篇 |
药学 | 296篇 |
中国医学 | 8篇 |
肿瘤学 | 856篇 |
出版年
2024年 | 6篇 |
2023年 | 86篇 |
2022年 | 107篇 |
2021年 | 252篇 |
2020年 | 154篇 |
2019年 | 218篇 |
2018年 | 272篇 |
2017年 | 169篇 |
2016年 | 195篇 |
2015年 | 201篇 |
2014年 | 308篇 |
2013年 | 358篇 |
2012年 | 506篇 |
2011年 | 517篇 |
2010年 | 284篇 |
2009年 | 251篇 |
2008年 | 403篇 |
2007年 | 384篇 |
2006年 | 342篇 |
2005年 | 403篇 |
2004年 | 338篇 |
2003年 | 307篇 |
2002年 | 259篇 |
2001年 | 34篇 |
2000年 | 28篇 |
1999年 | 36篇 |
1998年 | 63篇 |
1997年 | 45篇 |
1996年 | 38篇 |
1995年 | 32篇 |
1994年 | 27篇 |
1993年 | 23篇 |
1992年 | 12篇 |
1991年 | 10篇 |
1990年 | 15篇 |
1989年 | 12篇 |
1988年 | 13篇 |
1987年 | 6篇 |
1986年 | 12篇 |
1985年 | 5篇 |
1984年 | 7篇 |
1983年 | 3篇 |
1982年 | 5篇 |
1981年 | 4篇 |
1980年 | 6篇 |
1977年 | 3篇 |
1975年 | 2篇 |
1971年 | 2篇 |
1965年 | 2篇 |
1904年 | 2篇 |
排序方式: 共有6775条查询结果,搜索用时 15 毫秒
61.
62.
63.
Riccardo Dolcetti Paola Zancai Roberta Cariati Mauro Boiocchi 《Leukemia & lymphoma》1998,29(3):269-281
Retinoids have been shown to be effective in the chemoprevention and treatment of certain human malignancies. In this review, we will summarize our recent results concerning the effects of retinoids on the proliferation and differentiation of Epstein-Barr virus (EBV)-immortalized lymphoblastoid B-cell lines (LCLs), an in vitro model of EBV-related lymphoproliferative disorders arising in immunosuppressed hosts. Retinoids proved to be powerful inhibitors of the proliferation of EBV-infected LCLs in vitro, with 13-cis-retinoic acid (RA), all-trans-RA, and 9-cis-RA being the most effective compounds. Of note, retinoid-induced growth arrest in vitro appears irreversible at drug concentrations (10--6 mol/L) which may be reached in man after oral systemic therapy. The antiproliferative activity exerted by retinoids on LCLs is a generalized phenomenon usually associated with a progressive accumulation in G0/G1 phases of treated cells. The strong upregulation of p27Kipl invariably observed in cells exposed to retinoids may contribute to the decreased number of cycling cells, probably by inhibiting the transition from the G1 to S phase. Moreover, we obtained evidence indicating that the antiproliferative effects of retinoids are not dependent on the induction of terminal differentiation of EBV-immortalized B lymphocytes. In fact, the modifications induced by retinoids relative to LCL morphology, phenotype (downregulation of CD19, HLA-DR, and s-Ig, and upregulation of CD38 and c-Ig), and IgM production were highly variable among the lines tested and often only slightly relevant. Finally, the antiproliferative activity exerted by retinoids on LCLs is not mediated by a direct modulation of viral latent antigens, since EBNA-2 and LMP-1 downregulation was a late event detected only in some cell lines. These results indicate that retinoids may be useful in the medical treatment of EBV-related lymphoproliferative disorders of immunosuppressed patients, particularly in the earlier phases of these diseases. 相似文献
64.
Silvana Chiara Maria Teresa Nobile Maura Vincenti Rita Lionetto Alberto Gozza Maria Cristina Barzacchi Ornella Sanguineti Lazzaro Repetto Riccardo Rosso 《Cancer chemotherapy and pharmacology》1998,42(4):336-340
To evaluate toxicity and efficacy of chemotherapy in elderly patients (≥65 years of age) with advanced colorectal cancer,
data from two consecutive trials conducted between 1984 and 1995 at the National Institute for Cancer Research were analysed
comparing the results of treatment in those 65 years of age or older and in those younger than 65 years. Of 215 patients recruited,
82 elderly patients (median age 70 years, median performance status 1) received one of the following regimens based on 5-fluorouracil
(5-FU): (1) weekly 5-FU 600 mg/m2 i.v. bolus (30 patients); (2) weekly 5-FU 600 mg/m2 bolus plus leucovorin (LV) 500 mg/m2 2-h i.v. infusion (28 patients); (3) Weekly 5-FU 2600 mg/m2 24-h continuous i.v. infusion plus LV 100 mg 4-h i.v. infusion and 50 mg orally every 4 h for five doses (24 patients). Overall,
1071 chemotherapy cycles were administered with a median number of 12 courses per patient. The main side effects were diarrhoea,
observed in 38% of patients, stomatitis in 24% of patients and hand-foot syndrome in 13% of patients, and haematological toxicity
affected only 15% of patients. No patient suffered grade IV toxicity. In three patients chemotherapy was discontinued because
of toxicity (two patients suffered grade III diarrhoea, one patient grade III hand-foot syndrome). No significant difference
in toxicity was evident between patients older than or younger than 65 years. Analysis of median dose intensity demonstrated
no difference between the two groups. Overall objective response was observed in 18% (95% confidence limits 11–29) of elderly
patients (15/82) in comparison with 23% (95% CL 17–32) of patients <65 years of age (31/133 pts). In conclusion, chemotherapy
in elderly patients with advanced colorectal cancer is a safe and effective treatment with acceptable toxicity and comparable
objective response rates.
Received: 6 January 1998 / Accepted: 27 February 1998 相似文献
65.
Filippo Festini Riccardo Ciuti Giovanni Taccetti Teresa Repetto Silvia Campana Maurizio De Martino 《The journal of maternal-fetal & neonatal medicine》2006,19(6):375-376
We report the case of a 30-year-old woman with cystic fibrosis (CF) chronically infected with Pseudomonas aeruginosa who delivered and breast-fed a healthy boy. While breast-feeding the woman had to undergo an i.v. antibiotic course with tobramycin, due to pulmonary exacerbation. Tobramycin was not detected in her milk and lactation could be continued. This is the first time that the presence of tobramycin in the milk of a CF woman during i.v. administration has been investigated. 相似文献
66.
Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. 总被引:4,自引:0,他引:4
Paolo Giovanni Artini Massimiliano Monti Cristiana Matteucci Valeria Valentino Francesca Cristello Andrea Riccardo Genazzani 《Gynecological endocrinology》2006,22(8):465-470
BACKGROUND: Polycystic ovary syndrome (PCOS) is a common endocrine disorder that causes anovulation and consequent subfertility. It is well established that increased ovarian mass, supported by new blood vessel proliferation in stroma and theca, is a key feature of PCOS. Recent studies suggest a role for angiogenetic factors in this phenomenon. AIM: To evaluate of levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in serum and follicular fluid of PCOS patients during a controlled ovarian hyperstimulation. METHODS: In 52 patients undergoing in vitro fertilization treatments, 26 PCOS patients and 26 controls, serum VEGF and bFGF levels were assessed before starting administration of follicle-stimulating hormone (FSH) (day 0), on the day of administration of human chorionic gonadotropin (hCG) and on the day of oocyte retrieval. Follicular fluid levels of the two growth factors were detected on the day of oocyte retrieval. RESULTS: PCOS patients showed higher serum VEGF levels than controls before starting FSH administration, on the day of hCG administration and on the day of oocyte retrieval. Serum VEGF levels showed a rise after hCG administration only in the PCOS patients. In addition, serum bFGF levels were higher in PCOS patients than in controls on the day of hCG administration and the day of oocyte retrieval. Furthermore, on the day of hCG administration, serum bFGF levels were directly correlated to the amount of FSH previously administered (p < 0.0001). In follicular fluid, higher VEGF and bFGF levels were found in PCOS patients than in controls. Furthermore, follicular-fluid bFGF concentrations were inversely correlated with the percentage of mature oocytes collected (p < 0.05). CONCLUSIONS: The present study revealed elevated levels of VEGF and bFGF in serum and follicular fluid in PCOS patients compared with controls. bFGF seems to be an FSH-dependent growth factor and its levels in follicular fluid are inversely correlated with the percentage of mature oocytes collected. 相似文献
67.
Riccardo Valdagni Corrado Italia Paolo Montanaro Angelo Lanceni Paola Lattuada Tiziana Magnani Claudio Fiorino Alan Nahum 《Radiotherapy and oncology》2005,75(1):74-82
BACKGROUND AND PURPOSE: The objectives of the current study were to compare genito-urinary (GU) and gastro-intestinal (GI) toxicities as well as biochemical control (bRFS) in prostate cancer, utilizing conventional (2.0 Gy daily) (STD) or hyperfractionated (HFX) conformal irradiation (CRT). HFX (1.2 Gy BID) was chosen as a radiobiological method to try to reduce long term sequelae without compromising local control. PATIENTS AND METHODS: Three-hundred-and-seventy consecutive patients (pts) entered this prospective, non-randomized trial in the period January 1993-January 2003; 209 were treated with STD and 161 with HFX CRT. All were evaluable for acute toxicity analysis, 179 (STD) and 151 pts (HFX) being evaluable for late sequelae and bRFS analyses. Pt characteristics were not statistically different in the two groups. CRT consisted of a 4-field technique for prostate and/or pelvic nodes and a 5-field boost with rectal shielding. Median doses were 74 and 79.2 Gy for STD and HFX patients respectively, the latter dose being isoeffective for tumour control assuming alpha/beta=10 (EQD(2)=73.9 Gy). Median follow-up was 29.4 months (25.2 mos for STD; 37.7 mos for HFX; P<0.01). The two regimens were compared in terms of acute and late GU and GI toxicities and 5-year bRFS by univariate and multivariate analyses. RESULTS: Acute grade> or =2 GU toxicity was higher in the STD group (48.6% versus 37.3% in HFX, P=0.03), while no significant difference was found for acute GI toxicity. Late grade> or =2 GU and GI toxicities were lower in the HFX group (5-year actuarial rate: GU: 10.1% versus 20.3%, P=0.05; GI: 6.0% versus 10.6%, P=0.18). Five-year bRFS were 70% (+/-13.8%, 95% CI) and 82.6% (+/-7.2%) for STD and HFX, respectively (P=0.44); a trend favouring HFX was found in the subgroup of pts who did not receive hormonal therapy (5-year bRFS: 85.9%+/-12.4% versus 63.9%+/-23.8%, P=0.15). Multivariate analysis revealed only risk groups and age statistically related to bRFS but not fractionation regimen. Using the Nahum-Chapman TLCP model and prostate parameter set, which includes hypoxia, the TLCPs are approximately equal for the two regimens, whereas assuming alpha/beta=1.5 and no hypoxia we obtain 73% for the STD group but only 36% for the HFX group. CONCLUSIONS: As expected from radiobiological considerations, HFX reduces GI and GU late toxicities. Concerning early bRFS, our clinical findings suggest that HFX is no less effective than STD when delivering an isoeffective (alpha/beta=10) dose. Despite the relatively short follow-up, this result appears to be inconsistent with a low alpha/beta ratio for prostate cancer. 相似文献
68.
Serum PDGF-AB in pleural mesothelioma. 总被引:2,自引:0,他引:2
Rosa Filiberti Paola Marroni Monica Neri Andrea Ardizzoni Pier Giacomo Betta Mara A Cafferata Pier Aldo Canessa Riccardo Puntoni Giovanni Paolo Ivaldi Michela Paganuzzi 《Tumour biology》2005,26(5):221-226
Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean+2SD of PDGF-AB in healthy controls, 43% of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5% of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR=1.2, 95%CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM. 相似文献
69.
Barbara Longobardi Elena De Martin Claudio Fiorino Italo Dell'oca Sara Broggi Giovanni Mauro Cattaneo Riccardo Calandrino 《Radiotherapy and oncology》2005,77(2):148-156
BACKGROUND AND PURPOSE: To investigate the feasibility and the advantages of using Intensity-Modulated Radiotherapy (IMRT) for the treatment of head-and-neck cancer. Comparing different methods to deliver IMRT in this clinical setting. MATERIALS AND METHODS: Seven patients (four radical; three post-operative), treated on a 6MV Varian Linac (equipped with an 80 leaves MLC) in accordance with a routine 3DCRT plan, were replanned. Original treatment plans were computed to irradiate a primary Planning Target Volume (PTV1, 54 Gy) and then to perform a boost on a PTV2 (radical: 70.2 Gy; post-operative: 64.8 Gy). IMRT dose plans were inversely-optimized using appropriate constraints with the Helios tool on a Varian Eclipse system. Once the optimal fluences were calculated, different modalities to deliver IMRT were considered: Sliding Window (SW) and Step and Shoot (SS) techniques using a different number of intensity levels to approximate the optimal fluences (e.g. 5, 10 and 20). Mean dose, maximum dose and a number of dose-volume parameters regarding CTV1, CTV2, PTV1, PTV2, OARs (spinal and planning spinal cord, parotids, optical structures, brain and temporal mandibular joint) were considered to compare the five modalities (3DCRT, SW, SS5, SS10, SS20); the Conformity Index (CI), the Irradiated Volume (IV) and the Treated Volume (TV) were also considered in the comparison. RESULTS: A more uniform coverage of the PTV in the IMRT dose plans with respect to the 3DCRT plan was found (for PTV2: V90% = 94.3 for 3DCRT, 97.6 for SS5, 98 for SS10 and 98.1 for SW; V107% = 20.7 for 3DCRT, 5.9 for SS5, 2 for SS10 and 1.3 for SW). Concerning OARs, they all present a significant reduction of mean and/or maximum dose and dose-volume patterns assessed from DVHs: in particular the mean dose of parotids decrease on average of about 13.5Gy passing from 3DCRT to IMRT with an average reduction of NTCP ranging from about 20% to more than 40% for radically treated patients, depending on the chosen end-point. IV and TV are also slightly smaller with IMRT. The results obtained with SS techniques employing 10 or more intensity levels are comparable with those obtained with SW; no differences between SS10 and SW may be appreciated when considering the DVHs of PTV, CTV and OARs. On the other hand, in some cases SS5 may be slightly sub-effective with respect to SS10-SW when considering PTV coverage and Dmax of the spinal cord. CONCLUSIONS: With the Varian planning and delivery system, Step-and-shoot approximations of inversely optimised fluences in head-neck IMRT compare well with SW delivery, even with only five intensity levels. With a number of intensity level of 10 or more, no differences can be appreciated in PTV coverage/OAR sparing with respect to SW. 相似文献
70.